Biopharma Deals and Funding Trends – Review of 2022 and Updates through Q1 2023

Biopharma Deals and Funding Trends – Review of 2022 and Updates through Q1 2023

Deal Flow in 2022 Returned to pre-2019 Levels

Deal Flow in 2022 Returned to pre 2019 Levels

Lower Deal Dollars Across All Healthcare and Life Sciences

Lower Deal Dollars Across All Healthcare and Life Sciences

Licensing Terms are Shifting to More in Milestones

Licensing Terms are Shifting to More in Milestones

Large Cap Biopharma In-Licensing and Buying in 2022

Large Cap Biopharma In Licensing and Buying in 2022

Big Pharma Pays Well for Phase II as POC Returns

Big Pharma Pays Well for Phase II as POC Returns

Large Cap Biopharma Therapy Areas and Modalities in Focus

Large Cap Biopharma Therapy Areas and Modalities in Focus

R&D Partnership Activity in Oncology

RD Partnership Activity in Oncology

R&D Partnership Activity in Neurology

RD Partnership Activity in Neurology

R&D Partnership Upfronts in the Top Modalities

RD Partnership Upfronts in the Top Modalities 1

Healthcare and Life Sciences Venture Returned to pre-2020

Healthcare and Life Sciences Venture Returned to pre 2020

All Company Stages Saw Lower Venture Activity

All Company Stages Saw Lower Venture Activity

Biopharma M&A Volume Increased in Q1

Biopharma MA Volume Increased in Q1
Biopharma MA Volume Increased in Q1

All of this by stage, disease indication, modality, target…

+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures